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OBJECTIVE: To estimate the annual direct and indirect costs of the prevention and treatment of cervical cancer
in Brazil.
METHODS: This cost description study used a "gross-costing" methodology and adopted the health system and
societal perspectives. The estimates were grouped into sets of procedures performed in phases of cervical cancer
care: the screening, diagnosis and treatment of precancerous lesions and the treatment of cervical cancer. The
costs were estimated for the public and private health systems, using data from national health information
systems, population surveys, and literature reviews. The cost estimates are presented in 2006 USD.
RESULTS: From the societal perspective, the estimated total costs of the prevention and treatment of cervical
cancer amounted to USD $1,321,683,034, which was categorized as follows: procedures (USD $213,199,490),
visits (USD $325,509,842), transportation (USD $106,521,537) and productivity losses (USD $676,452,166).
Indirect costs represented 51% of the total costs, followed by direct medical costs (visits and procedures) at 41%
and direct non-medical costs (transportation) at 8%. The public system represented 46% of the total costs, and
the private system represented 54%.
CONCLUSION: Our national cost estimates of cervical cancer prevention and treatment, indicating the economic
importance of cervical cancer screening and care, will be useful in monitoring the effect of the HPV vaccine
introduction and are of interest in research and health care management.
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Cervical cancer is the second most frequent cancer in
women in Brazil, with an estimated incidence rate of 19 per
100,000 women, according to the National Cancer Institute –
INCA in 2010 (1). The average adjusted mortality rate was
estimated to be 7 per 100,000 women in 2008 (2).
Secondary prevention (screening and treatment of pre-
cancerous lesions) has successfully reduced the incidence
and mortality rates of cervical cancer in many high-income
countries. However, in low- and middle-income countries,
screening programs have had less impact, mainly because of
the limited coverage, poor performance of the Pap smear,
and irregular access and quality of treatment (3). The
primary prevention of cervical cancer and HPV infection
involves health promotion, sexual education, condom use
promotion, and, more recently, HPV vaccination (4,5). HPV
vaccines are considered efficacious in preventing persistent
HPV 16 and 18 infection and consequent precancerous
cervical lesions, and post-marketing surveillance in devel-
oped countries has so far been positive regarding their
effectiveness and safety (6,7).
In previously published economic evaluations, introdu-
cing the HPV vaccine as part of the routine immunization
schedule in Brazil was considered cost-effective (8–11).
In 2009, the Brazilian Ministry of Health commissioned a
cost-effectiveness study to investigate the introduction of the
HPV vaccine as part of the National Immunization Program;DOI: 10.6061/clinics/2015(04)12
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the study found the HPV immunization of girls to be cost-
effective (4). The universal HPV vaccination of girls aged 11
to 13 years was introduced in March 2014.
In Brazil, the public (Sistema Único de Saúde, SUS) and
private health systems have made large investments in the
prevention and treatment of cervical cancer, but no studies
have been published with detailed cost estimates of the
components and specific technologies involved. This study
was the preliminary step of a cost-effectiveness analysis, and
its objective was to estimate the annual direct and indirect
costs of the prevention and treatment of cervical cancer in
Brazil, based on national data available in public health
information systems.
Knowing the cost of the prevention and treatment of
cervical cancer in the health care system and for the
population is important as baseline information for future
budget effect analyses of the vaccination program. Addi-
tionally, these national public and private cost estimates are
of interest for making other public health management and
policy decisions and for international comparisons.
’ MATERIALS AND METHODS
This is a descriptive study of the costs of the prevention
and treatment of cervical cancer in Brazil, in 2006.
Based on specialized publications and clinical guidelines
(12), the estimates were grouped into sets of procedures
performed in different phases of cervical cancer care:
screening; diagnosis and treatment of precancerous lesions –
cervical intraepithelial neoplasia (CIN-I and CIN-II/III); and
treatment of cervical cancer. The costs were estimated for the
public and private health systems.
The study adopted the health system perspective, estimat-
ing direct medical costs (outpatient visits, diagnostic tests,
procedures, clinical treatment, surgical interventions, medi-
cations and hospitalizations) and the societal perspective,
with estimations of direct non-medical costs (transportation)
and indirect costs resulting from productivity losses related
to illness.
The costing was performed using the "gross-costing"
methodology. All the cost estimates were converted from
Brazilian Reals (BRL) to 2006 United States dollars (USD) at
the exchange rate of USD $1 = BRL $2.1642.
Direct medical costs in the public health
system (SUS)
The data sources used for estimating health service
utilization and costs in the SUS were the Primary Care
Information System (SIAB), the Outpatient Information System
(SIA/SUS), the Authorizations for High Complexity Procedures
(APAC), the Cervical Cancer Information System (SISCOLO),
and the Hospitalization Information System (SIH/SUS).
Hospitalizations, procedures and visits were identified
using the International Classification of Diseases (ICD-10)
codes related to cervical cancer (C53.0, C53.1, C53.8 and
C53.9). The codes for the procedures and their unit costs
were retrieved from the Table of Procedures, Drugs,
Orthotics, Prosthetics and Special Materials (SIGTAP) and
The Health Prices Database (BPS) of the Ministry of Health.
To estimate screening costs, we identified the number of
Pap smears performed and the number of medical and
nursing visits associated with the procedure based on routine
primary health care.
The diagnosis of precancerous lesions included colposcopy
and cervical biopsy. The treatment of precancerous lesions
(CIN-I, CIN-II/III) included cold knife conization, the loop
electrosurgical excision procedure (LEEP), trachelectomy,
vaginal enlarged amputation of the cervix, and hysterectomy.
The estimates for the surgical treatment of cervical cancer
included all inpatient abdominal hysterectomies because of
tumors. Leiomyomas are the most frequent cause of
hysterectomy and, based on expert opinion and the
literature, we assumed that cervical cancer was the cause
of 20% of abdominal hysterectomies in 2006 in Brazil (13).
For vaginal hysterectomies, we assumed that only 5% were
performed to treat precancerous lesions, based on expert
opinion. The clinical treatment of cervical cancer included
hospitalizations, chemotherapy, radiotherapy and additional
complementary complex procedures.
Direct medical costs in the private health system
We estimated the level of participation in the private
health system based on data from the 2008 Health Supple-
ment of the National Survey of Household Samples (PNAD).
Frequencies of the procedures in the private health system
were estimated based on the pattern of care provided by the
SUS. To estimate costs in the private health system, the
procedures were valued based on the National Table of
Equivalence of Procedures (TUNEP).
Direct non-medical costs
The direct non-medical costs were the costs of patient
transportation for procedures and visits. They were esti-
mated based on the average fare of public transportation in
the Brazilian state capitals (USD $0.87) obtained from the
National Association of Urban Transport (NTU).
Indirect costs
Indirect costs represent the working days lost by the
patient and caregiver for preventing, diagnosing and treating
the disease. We adopted the Human Capital Method and
considered the average monthly income of women over 15
years weighted by the participation in the labor market to
estimate the average daily income (USD $11.05).
’ RESULTS
Direct medical costs in the public health
system (SUS)
Table 1 presents the estimates of the frequency and costs of
procedures and visits related to the prevention and treatment
of cervical cancer in the SUS and the private health system,
in 2006 USD. Despite the low unit cost, screening was the
procedure with the highest cost (USD $47,794,327) because of
its frequency and associated visits. The diagnosis and
treatment of precancerous lesions were estimated to cost
USD $9,253,598 and USD $3,653,569, respectively, which
were approximately 20% and 8% of the screening costs.
Inpatient surgical treatment was estimated at USD
$7,650,810, and clinical treatment, including hospital admis-
sions, other clinical procedures and clinical oncology out-
patient treatment of cervical cancer, was estimated at USD
$36,448,391.
The total estimated costs of the screening, diagnosis and
treatment of precancerous lesions and the surgical and
clinical treatment of cervical cancer, paid by SUS in 2006, was
USD $104,966,045: 45.7% on screening, 8.8% on diagnostic
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procedures of precancerous lesions, 3.5% on therapeutic
procedures for precancerous lesions, 7.3% on surgical
interventions for cancer, and 34.7% on clinical treatment for
cervical cancer (Figure 1).
The costs of medical visits were an important component
of the estimated costs of screening (USD $18,924,336) and the
diagnosis of precancerous lesions (USD $7,653,178). The
estimated total cost of the visits was USD $28,336,826, which
accounted for 27% of the total direct medical costs.
Direct medical costs in the private health system
According to a national household survey, the PNAD 2008,
25.9% of the Brazilian population had private health
insurance and access to private healthcare, but the utilization
of the private health system varied according to the complex-
ity of care; the utilization was 35.8% for cervical cancer
screening and 26.9% for the diagnosis and treatment of
precancerous lesions and cervical cancer. These proportions
were used to estimate the number of procedures in the
private health system.
Screening was by far the procedure with the highest cost
(USD $368,191,899) because of its frequency, associated visits
and associated higher costs in the private system (Table 1). The
estimated costs for the diagnosis and treatment of precancer-
ous lesions (USD $32,813,663 and USD $5,750,416) were
approximately 9% and 1.5% of the screening costs, respectively.
Inpatient surgical treatment was estimated at USD $6,950,099,
and clinical treatment, including hospital admissions, clinical
procedures and clinical oncology outpatient treatment of
cervical cancer, was estimated at USD $20,037,207.
The estimated costs related to cervical cancer in the private
health system were USD $433,743,286 in 2006, with 84.9%
spent on screening, 7.6% on diagnostics, 1.3% on therapeutic
procedures for precancerous lesions, 1.6% on surgical
Table 1 - Estimates of direct medical costs for the screening, diagnosis and treatment of precancerous lesions and the
diagnosis and treatment of cervical cancer in public and private health systems in Brazil, in 2006 United States dollars
(USD).
Public Health System Private Health System










Pap smears 11,701,728 2.48 29,035,338.40 6,552,968 15.53 101,737,235.38
Visits 23,403,456 0.81 18,924,336.01 13,105,936 20.33 266,454,664.08
Total 47,959,674.41 368,191,899.45
Diagnosis of precancerous lesions
Colposcopy 972,764 0.78 759,620.72 340,467 20.84 7,095,028.97
Cervical biopsy 124,124 6.77 840,799.30 43,443 17.08 741,915.39
Subtotal - Procedures 1,096,888 1,600,420.02 383,910 7,836,944.36
Visits 2,193,776 3.49 7,653,178.45 614,257 20.33 24,976,719.34
Total 9,253,598.47 32,813,663.70
Treatment of precancerous lesions
Loop electrosurgical excisional
procedure (LEEP)
66,870 8.71 582,432.08 23,405 89.46 2,093,710.38
Cold knife conization 8,766 176.91 1,550,758.14 3,068 377.20 1,157,240.75
Vaginal hysterectomy 641 188.22 120,650.29 224 701.64 157,168.47
Trachelectomy 2,986 251.64 751,398.02 1,045 463.25 484,093.52
Vaginal enlarged amputation of the cervix 217 432.19 93,785.67 76 636.75 48,392.85
Subtotal - Procedures 79,480 3,099,024.19 27,818 3,940,605.97
Visits 158,960 3.49 554,545.79 44,509 20.33 1,809,810.55
Total 3,653,569.98 5,750,416.52
Surgical treatment of cervical cancer
Radical hysterectomy (Wertheim-Meigs) 1,474 304.20 448,391.05 516 803.29 414,497.59
Total hysterectomy 12,008 234.32 2,813,684.91 4,203 735.36 3,090,725.63
Extended radical hysterectomy 3,231 1,215.06 3,925,869.53 1,131 2,087.46 2,360,916.77
Tumor total hysterectomy 642 438.06 281,231.72 225 2,183.26 491,234.41
Subtotal - Procedures 17,355 7,469,177.20 6,075 6,357,374.40
Visits 52,065 3.49 181,633.28 9,718 20.33 592,725.26
Total 7,650,810.48 6,950,099.65
Clinical treatment of cervical cancer
Hospitalizations 28,057 301.78 8,467,141.60 9,820 488.43 4,796,427.04
Other medical procedures 10,223 264.07 2,699,586.22 3,578 488.43 1,747,618.73
Complex medical procedures listed in
APAC*
20,789 488.43 10,154,065.35
Subtotal - Procedures 97,760 35,425,259.03 34,187 16,698,111.12
Visits 293,280 3.49 1,023,132.80 54,746 20.33 3,339,096.20
Total - Clinical treatment 36,448,391.83 20,037,207.32
TOTAL 104,966,045.17 433,743,286.66
*APAC = Authorizations for High Complexity Procedures (Autorizac¸o˜es de Procedimentos de Alta Complexidade)
Source of data for the Public Health System: the Table of Procedures, Drugs, Orthotics, Prosthetics and Special Materials (Tabela de Procedimentos,
Medicamentos e O´rteses, Pro´teses e Materiais especiais do SUS) and the Outpatient Information System (Sistema de Informac¸o˜es Ambulatoriais do SUS,
SIA/SUS).
Source of data for the Private Health System: the National Table of Equivalence of Procedures (Tabela U´nica Nacional de Equivaleˆncia de Procedimentos,
TUNEP), the Health Supplement of the National Survey of Household Samples (Pesquisa Nacional por Amostra de Domicı´lios, PNAD), and the
Hospitalization Information System (Sistema de Informac¸o˜es Hospitalares do SUS, SIH/SUS).
291
CLINICS 2015;70(4):289-295 Annual national cost of cervical cancer in Brazil
Novaes HM et al.
interventions and 4.6% on clinical treatment for cervical
cancer (Table 1, Figure 1).
The costs of medical visits were estimated separately and
were a particularly important aspect of the estimated costs of
screening (USD $266,454,664) and the diagnosis of precan-
cerous lesions (USD $24,976,719). The estimated total cost of
the visits was USD $297,173,015, accounting for 69% of the
total direct medical costs.
Table 2 - Estimates of non-medical direct costs (transportation) associated with the screening, diagnosis and treatment
of precancerous lesions and the diagnosis and treatment of cervical cancer in the public and private health systems in
Brazil, in 2006 United States dollars.
Transportation costs
Public System Private System
Cervical cancer care components Procedures Visits Procedures Visits
Screening
Pap smears 20,438,282.89 40,876,565.79 11,445,438.42 22,890,876.84
Total Screening 20,438,282.89 40,876,565.79 11,445,438.42 22,890,876.84
Diagnosis of precancerous lesions
Colposcopy 1,699,033.32 3,398,066.65 951,458.66 1,902,917.32
Cervical biopsy 216,795.45 433,590.91 121,405.45 242,810.91
Total diagnosis of precancerous lesions 1,915,828.78 3,831,657.55 1,072,864.12 2,145,728.23
Treatment of precancerous lesions
Loop electrosurgical excisional procedure (LEEP) 116,795.40 233,590.80 65,405.42 130,810.84
Cold knife conization 15,310.73 30,621.46 8,574.01 17,148.02
Vaginal hysterectomy 1,119.57 2,239.15 626.96 1,253.92
Trachelectomy 5,215.36 10,430.72 2,920.60 5,841.20
Vaginal enlarged amputation of the cervix 379.01 758.03 212.25 424.49
Total treatment of precancerous lesions 138,820.07 277,640.14 77,739.24 155,478.48
Surgical treatment of cervical cancer
Radical hysterectomy (Wertheim-Meigs procedure) 2,574.49 7,723.48 1,441.72 4,325.15
Total hysterectomy 20,973.22 62,919.66 11,745.00 35,235.01
Extended radical hysterectomy 5,643.28 16,929.83 3,160.23 9,480.70
Tumor total hysterectomy 1,121.32 3,363.96 627.94 1,883.82
Total surgical treatment 30,312.31 90,936.93 16,974.89 50,924.68
Clinical treatment of cervical cancer
Hospitalizations 49,004.46 147,013.39 27,442.50 82,327.50
Other medical procedures 17,855.53 53,566.59 9,999.10 29,997.29
Complex procedures (listed in APAC) 103,888.00 311,663.99 58,177.28 174,531.83
Total clinical treatment 170,747.99 512,243.97 95,618.88 286,856.62
Subtotal 22,693,992.04 45,589,044.39 12,708,635.55 25,529,864.86
Total (by system) 68,283,036.43 38,238,500.40
TOTAL 106,521,536.83
Source: Estimates based on the average public transport fare in the Brazilian capitals from the National Association of Urban Transport (Associac¸a˜o
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Figure 1 - Estimates costs distribution (%) by cervical cancer care components in Brazil, 2006.
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Summing the estimated direct medical costs in the public
(USD $104,966,045) and private health systems (USD
$433,743,287), the estimated total direct medical cost of
cervical cancer was USD $538,709,332 in 2006.
Direct non-medical costs
The total estimated cost of transportation was USD
$106,521,536 (Table 2), 64% of which was related to care in
the public health system because of higher procedure
Table 3 - Estimates of indirect costs (productivity loss) associated with the screening, diagnosis and treatment of
precancerous lesions and the diagnosis and treatment of cervical cancer in the public and private health systems in
Brazil, in 2006 United States dollars.
Productivity loss
Public System Private System
Cervical cancer care components No of days lost Procedures Visits Procedures Visits
Screening
Pap smears 1 129,280,250 258,560,499 72,396,940 144,793,879
Total screening 129,280,250 258,560,499 72,396,940 144,793,879
Diagnosis of precancerous lesions
Colposcopy 1 10,747,060 21,494,120 6,018,354 12,036,707
Cervical biopsy 1 1,371,317 2,742,635 767,938 1,535,875
Total diagnosis of precancerous lesions 12,118,377 24,236,754 6,786,291 13,572,582
Treatment of precancerous lesions
Loop electrosurgical excisional procedure (LEEP) 1 738,777 1,477,554 413,715 827,430
Cold knife conization 2 154,954 193,693 86,774 108,468
Vaginal hysterectomy 3 24,078 14,164 13,484 7,931
Trachelectomy 2 62,680 65,979 35,101 36,948
Vaginal enlarged amputation of the cervix 3 6,473 4,795 3,625 2,685
Total treatment of precancerous lesions 986,962 1,756,184 552,699 983,463
Surgical treatment of cervical cancer
Radical hysterectomy (Wertheim-Meigs procedure) 5 74,909 48,854 41,949 27,358
Total hysterectomy 3 424,525 397,992 237,734 222,875
Extended radical hysterectomy 6 207,037 107,088 115,940 59,969
Tumor total hysterectomy 4 28,371 21,279 15,888 11,916
Total surgical treatment 734,842 575,213 411,511 322,119
Clinical treatment of cervical cancer
Hospitalizations 4 1,363,880 929,918 763,773 520,754
Other medical procedures 1 112,943 338,830 63,248 189,745
Complex procedures(listed in APAC) 1 657,133 1,971,398 367,994 1,103,983
Total clinical treatment 2,133,956 3,240,146 1,195,015 1,814,482
Subtotal 145,254,387 288,368,797 81,342,456 161,486,525
Total (by system) 433,623,184 242,828,982
TOTAL 676,452,166
Source: Estimates based on the Health Supplement of the National Survey of Household Samples (Pesquisa Nacional por Amostra de Domicı´lios, PNAD)
and the Hospitalization Information System (Sistema de Informac¸o˜es Hospitalares do SUS, SIH/SUS).
Table 4 - Total annual costs of prevention and treatment of cervical cancer in Brazil according to health system, in 2006
United States dollars.
Public System Private System
Cervical cancer care components Direct Indirect Total Direct Indirect Total
Health System Perspective
Screening 47,959,674 47,959,674 368,191,899 368,191,899
Diagnosis of precancerous lesions 9,253,598 9,253,598 32,813,664 32,813,664
Treatment of precancerous lesions 3,653,570 3,653,570 5,750,417 5,750,417
Surgical treatment of cervical cancer 7,650,810 7,650,810 6,950,100 6,950,100
Clinical treatment of cervical cancer 36,448,392 36,448,392 20,037,207 20,037,207
Total 104,966,045 104,966,045 433,743,287 433,743,287
Total by system 104,966,045 433,743,287
TOTAL 538,709,332
Societal Perspective
Screening 109,274,523 387,840,749 497,115,272 402,528,215 217,190,819 619,719,034
Diagnosis of precancerous lesions 15,001,085 36,355,132 51,356,216 36,032,256 20,358,874 56,391,130
Treatment of precancerous lesions 4,070,030 2,743,146 6,813,176 5,983,634 1,536,162 7,519,796
Surgical treatment of cervical cancer 7,772,060 1,310,055 9,082,114 7,017,999 733,630 7,751,629
Clinical treatment of cervical cancer 37,131,384 5,374,103 42,505,486 20,419,683 3,009,497 23,429,180
Total 173,249,082 433,623,184 606,872,266 471,981,787 242,828,982 714,810,769
Total by system 606,872,266 714,810,769
TOTAL 1,321,683,034
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and visit frequencies. The direct non-medical costs were
highest for screening in both the public and private health
systems.
Indirect costs
The estimated total indirect cost was USD $676,452,166.
Working days lost as the result of medical procedures
and visits in the public system represented 21% and 43%
of indirect costs, respectively, whereas working days lost
as the result of procedures and visits in the private
health system represented 12% and 24%, respectively
(Table 3).
Table 4 presents the estimated total costs of the prevention
and treatment of cervical cancer in Brazil from a societal
perspective, which amounts to USD $1,321,683,034, which
was spent on procedures (USD $213,199,490), visits (USD
$325,509,842), transportation (USD $106,521,537) and pro-
ductivity losses (USD $676,452,166).
The indirect costs represented 51% of the total costs,
followed by direct medical costs (visits and procedures) at
41% and direct non-medical costs (transportation) at 8%. The
public health system represented 46% of the total costs, and
the private health care system represented 54%.
’ DISCUSSION
Studies of the economic burden of cervical cancer in
developed countries use different methodological strategies
regarding the population under study (national or specific
groups), health services utilization and cost sources (indivi-
dual health care data, health information systems and
literature), diseases included (all HPV-related cancers, all
genital cancers or cervical cancer only), and study design and
perspective (14–16). The national annual cost of illness
results are dependent on the population size and are
influenced by the characteristics of the healthcare system.
In Belgium, the national annual cost of the management of
cervical cancer was estimated at approximately h$8 million
from a societal perspective (14). In France, the national direct
annual medical costs for invasive cervical cancer were
estimated at h$84 million (15).
A study that estimated the annual direct costs of the
screening, diagnosis and treatment of precancerous lesions and
the treatment of cervical cancer for the US in 2010 was more
similar to our study (16). The total estimated annual direct
costs related to cervical cancer were USD $7 billion: 76% on
screening, 18% on the diagnosis and treatment of precancerous
lesions, and 6% on cervical cancer treatment. Another US
study estimated that in 2005, the annual direct costs of
screening were USD $3.5 billion: 70% on screening, 19% on
precancerous lesions and 11% on cervical cancer treatment (17).
The estimated costs of diseases are lower in Brazil than in
high-income countries because of more limited access and
utilization of health services, lower average costs of
healthcare and lower family income; this also applies to
cervical cancer. The total annual direct costs in Brazil in 2006
were estimated at USD $538,709,332: 77% on screening, 10%
on precancerous lesions and 13% on cervical cancer treat-
ment. However, the estimated cost distribution in the public
health care system was 46%, 12% and 42% and in the private
health care system was 85%, 9% and 6%, respectively,
revealing very important differences in the proportional
weight of the components in the two systems.
These differences are a consequence of the different
relative weights of the estimated costs of procedures in the
two systems, with a larger difference in screening procedure
estimates than in cervical cancer treatment estimates;
however, the differences could also signal a higher incidence
of cervical cancer in the public health system population. In a
population with an effective screening program, it is to be
expected that the cervical cancer incidence is low, and
treatment costs will also be low. The effect of screening on
precancerous lesion costs is more uncertain, although a
reduction could also be expected.
Implementing an HPV immunization program for girls
will not have a short-term effect on precancerous lesions and
cervical cancer costs. New screening technologies and
programs will affect all cost estimates, possibly even from
a short-term perspective.
Non-medical direct costs and indirect costs comprise 60% of
the total estimated costs; however, these costs are more subject
to uncertainties than direct medical costs. This finding signaled
the importance of including these estimates in the annual costs
of cervical cancer care for society. The high number of
procedures required for prevention and care results in large
transportation expenses and many work-days lost, and the
socio-economic consequences of cervical cancer on patients
and families is a social cost that should not be ignored (18).
A detailed analysis of care components and specific
technologies allows for additional interesting observations,
particularly for the pattern of surgical procedures for
precancerous lesions and cervical cancer. Hysterectomies
for benign indications have been falling in most developed
countries, and less aggressive procedures have become more
frequent, whereas their number remains relatively stable for
gynecologic cancer and represents approximately 10% of all
hysterectomies in the US (19–22). Radical hysterectomy
remains an essential treatment option for women with
cancer in the early stages of cervical cancer, alongside
radiotherapy, but less intensive interventions are also being
considered. Our results indicate a predominance of the more
invasive surgical procedures (23,24).
To develop the estimates of health service utilization and
costs of the prevention and treatment of cervical cancer, this
study sought to optimize the use of available data in health
information systems and secondary databases, supplemen-
ted with data from literature reviews. The cost methodology
adopted—"gross costing", which is based on the average
reimbursement of procedures—is a recommended alterna-
tive to costing health services, particularly from a national
perspective (25). Cost estimates tend to be more conservative
but have the advantage of national representativeness,
reproducibility and comparability with other studies.
An important methodological issue is the uncertainty
regarding the frequency and remuneration of diagnostic and
therapeutic procedures for precancerous lesions and of
surgical interventions for cancer in the private health system.
The costs of the clinical treatment of cancer in the private
system may be more comparable to the public system; there
are no significant differences in treatment protocols.
The frequency of medical visits for the clinical treatment of
cancer may have been underestimated in both public and
private health systems.
There is uncertainty in the estimates of productivity losses
as the result of surgical interventions in both the public and
private health systems. Furthermore, in the clinical treatment
of cervical cancer, the loss of productivity other than days
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lost for performing the procedures was not included, nor
were the costs for families requiring drugs and other
products and services not provided by health services,
resulting in an underestimation of indirect costs.
Our cost estimates for cervical cancer prevention and
treatment, albeit subject to uncertainties and underestima-
tion, reveal little known values and patterns of direct and
indirect costs for the components of care in the public and
private health systems, indicating the complexity and
economic importance of cervical cancer screening and care,
and are of interest in research and health care management.
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